Literature DB >> 1342959

A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues.

R J Slebos1, L Boerrigter, S G Evers, P Wisman, W J Mooi, S Rodenhuis.   

Abstract

The use of the polymerase chain reaction (PCR) to detect specific DNA sequences in small amounts of tissues or cells has become a widespread tool in the field of molecular biology. With the better understanding of the clinical significance of oncogene activations in human tumors, the application of PCR in a routine setting is rapidly gaining importance. We have developed a rapid and simple procedure for the detection of mutated ras oncogenes in routinely fixed, paraffin-embedded tissue samples. DNA is isolated from three 10 microns tissue sections by incubation with a nonionic detergent and proteinase K, and can be directly used for amplification by PCR. The amplified DNA fragments are then dot-blotted onto nylon membranes and are hybridized to radioactively labeled oligodeoxynucleotides, specific for each of the mutated ras sequences. After a selective washing procedure, only fully matched oligodeoxynucleotides remain bound to the membrane, thus revealing the nature of the sequences that were present in the starting material. With this method, the detection of point mutations in ras genes can be performed in a routine setting, and the results of the analyses can be available in as few as 3-4 days.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1342959

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  9 in total

1.  Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients.

Authors:  R H Hruban; P D Sturm; R J Slebos; R E Wilentz; A R Musler; C J Yeo; T A Sohn; M L van Velthuysen; G J Offerhaus
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Peutz-Jeghers polyps, dysplasia, and K-ras codon 12 mutations.

Authors:  M M Entius; A M Westerman; F M Giardiello; M L van Velthuysen; M M Polak; R J Slebos; J H Wilson; S R Hamilton; G J Offerhaus
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

Review 3.  Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer.

Authors:  R Milroy; F Macbeth
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

4.  Clinical significance of K-ras oncogene activation in ampullary neoplasms.

Authors:  C H Chung; R E Wilentz; M M Polak; T B Ramsoekh; L A Noorduyn; D J Gouma; K Huibregtse; G J Offerhaus; R J Slebos
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

5.  Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity.

Authors:  R E Wilentz; M Goggins; M Redston; V A Marcus; N V Adsay; T A Sohn; S S Kadkol; C J Yeo; M Choti; M Zahurak; K Johnson; M Tascilar; G J Offerhaus; R H Hruban; S E Kern
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

6.  Synchronous colon carcinomas: molecular-genetic evidence for multicentricity.

Authors:  R J Koness; T C King; S Schechter; S F McLean; C Lodowsky; H J Wanebo
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

7.  Absence of ras gene mutations in early gastric carcinomas.

Authors:  M E Craanen; P Blok; B Top; L Boerrigter; W Dekker; G J Offerhaus; G N Tytgat; S Rodenhuis
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

8.  C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

Authors:  J A Kern; R J Slebos; B Top; S Rodenhuis; D Lager; R A Robinson; D Weiner; D A Schwartz
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

9.  Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients.

Authors:  Abeer A Bahnassy; Abdel-Rahman N Zekri; Soumaya El-Houssini; Amal M R El-Shehaby; Moustafa Raafat Mahmoud; Samira Abdallah; Mostafa El-Serafi
Journal:  BMC Gastroenterol       Date:  2004-09-23       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.